Showing results (141-150 of 159) with videos related to

Sort By:
Pageof 16
Acta Neuropathologica|June 27, 2023
SMN regulates GEMIN5 expression and acts as a modifier of GEMIN5-mediated neurodegenerationTyler R Fortuna, Sukhleen Kour, Anuradha Venkatakrishnan Chimata, et al.
British Journal of Cancer|March 13, 2018
A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumoursJordan Berlin, Ramesh K Ramanathan, John H Strickler, et al.
Translational Psychiatry|January 19, 2021
The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically illJennifer M Knight, Erin S Costanzo, Suraj Singh, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 11, 2015
Dynamic epigenetic regulation of glioblastoma tumorigenicity through LSD1 modulation of MYC expressionDavid Kozono, Jie Li, Masayuki Nitta, et al.
The New England Journal of Medicine|December 30, 2025
An Intravenous Brain-Penetrant Enzyme Therapy for Mucopolysaccharidosis IIJoseph Muenzer, Barbara K Burton, Paul Harmatz, et al.
EJNMMI Research|January 20, 2017
A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB-IIIA resectable NSCLCJohn P Crandall, Abdel K Tahari, Rosalyn A Juergens, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2018
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancerDavid E Gerber, Mark A Socinski, Joel W Neal, et al.
Indian Journal of Cancer|March 23, 2021
Survival outcomes with 12 weeks of adjuvant or neoadjuvant trastuzumab in breast cancerJoydeep Ghosh, Deepa S Joy Phillip, Jaya Ghosh, et al.
Journal for Immunotherapy of Cancer|August 8, 2022
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumorsRachel E Sanborn, Michael J Pishvaian, Margaret K Callahan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2026
Safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy from a first-in-human study of volrustomig, a novel PD-1/CTLA-4 bispecific antibodyBen Tran, Mark Voskoboynik, Sang-We Kim, et al.
Pageof 16